Development of novel vaccine candidates and challenge models for Plasmodium vivax
Plasmodium vivax is the most widely distributed human malaria parasite in the world and despite nearly 2.5 billion people living at risk, only four vaccines have been assessed in phase I clinical trials and only one has progressed to a phase II trial showing no sterile efficacy. We started to develo...
Main Authors: | Alves, E, Salman, A, Janse, C, Khan, S, Hill, A, Reyes-Sandoval, A |
---|---|
פורמט: | Journal article |
יצא לאור: |
BioMed Central
2014
|
פריטים דומים
-
Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine
מאת: Alves, E, et al.
יצא לאור: (2017) -
A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles
מאת: Alba Marina Gimenez, et al.
יצא לאור: (2021-09-01) -
Plasmodium vivax malaria vaccines: why are we where we are?
מאת: Reyes-Sandoval, A, et al.
יצא לאור: (2013) -
The challenges of Plasmodium vivax human malaria infection models for vaccine development
מאת: Roobsoong, W, et al.
יצא לאור: (2023) -
Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models
מאת: Salman, A, et al.
יצא לאור: (2017)